The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomized Trial

Inclusion Criteria: * Histologically confirmed squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the cervix, FIGO stage IB2-IVA * Planned for radical radiotherapy and concurrent cisplatin chemotherapy. * Able to receive weekly cisplatin. * No prior anticancer treatment for cervical cancer * ECOG 0 or 1 * Life expectancy of greater than 3 months. * Normal organ and marrow function * Able to take oral medications. * Ability to understand and willing to sign the consent form * Willing to undergo biopsies of cervical tumor. Exclusion Criteria: * Evidence of distant metastases * Receiving any other investigational agents concurrently or within 4 weeks. * Known diabetes mellitus. * Currently taking metformin, sulfonylureas, thiazolidinediones or insulin. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to metformin or cisplatin. * Any condition associated with increased risk of metformin-associated lactic acidosis * Uncontrolled inter-current illness * Pregnant women * History of another invasive malignancy, except for non-melanoma skin cancer or tumors curatively treated with no evidence of disease for \>=5 years. * Known HIV-positive * History of bowel obstruction or malabsorption syndromes * History of active clinically significant bleeding * Contraindications to radiotherapy * Taking drug disulfiram (antabuse).